DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Inrebic is a drug marketed by Impact and is included in one NDA. There are four patents protecting this drug.
This drug has seventy-nine patent family members in thirty-four countries.
The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this compound. Additional details are available on the fedratinib hydrochloride profile page.
Inrebic will be eligible for patent challenges on August 16, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 4, 2032. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for INREBIC
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||90|
|Drug Prices:||Drug price information for INREBIC|
|What excipients (inactive ingredients) are in INREBIC?||INREBIC excipients list|
|DailyMed Link:||INREBIC at DailyMed|
DrugPatentWatch® Estimated Generic Entry Opportunity Date for INREBIC
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Country||Patent Number||Estimated Expiration|
|Brazil||PI0618179||Get Started for $10|
|South Korea||101467723||Get Started for $10|
|Dominican Republic||P2013000097||Get Started for $10|
|South Korea||20130137647||Get Started for $10|
|South Korea||20180122029||Get Started for $10|
|South Korea||101494468||Get Started for $10|
|Russian Federation||2012103850||Get Started for $10|
|>Country||>Patent Number||>Estimated Expiration|